» Articles » PMID: 35435496

Infiltrative Growth Pattern of Prostate Cancer is Associated with Lower Uptake on PSMA PET and Reduced Diffusion Restriction on MpMRI

Abstract

Purpose: Recently, a significant association was shown between novel growth patterns on histopathology of prostate cancer (PCa) and prostate-specific membrane antigen (PSMA) uptake on [Ga]PSMA-PET. It is the aim of this study to evaluate the association between these growth patterns and ADC (mm/1000 s) values in comparison to [Ga]PSMA uptake on PET/MRI.

Methods: We retrospectively evaluated patients who underwent [Ga]PSMA PET/MRI for staging or biopsy guidance, followed by radical prostatectomy at our institution between 07/2016 and 01/2020. The dominant lesion per patient was selected based on histopathology and correlated to PET/MRI in a multidisciplinary meeting, and quantified using SUV for PSMA uptake and ADC for diffusion restriction. PCa growth pattern was classified as expansive (EXP) or infiltrative (INF) according to its properties of forming a tumoral mass or infiltrating diffusely between benign glands by two independent pathologists. Furthermore, the corresponding WHO2016 ISUP tumor grade was evaluated. The t test was used to compare means, Pearson's test for categorical correlation, Cohen's kappa test for interrater agreement, and ROC curve to determine the best cutoff.

Results: Sixty-two patients were included (mean PSA 11.7 ± 12.5). The interrater agreement between both pathologists was almost perfect with κ = 0.81. While 25 lesions had an EXP-growth with an ADC of 0.777 ± 0.109, 37 showed an INF-growth with a significantly higher ADC of 1.079 ± 0.262 (p < 0.001). We also observed a significant difference regarding PSMA SUV for the EXP-growth (19.2 ± 10.9) versus the INF-growth (9.4 ± 6.2, p < 0.001). Within the lesions encompassing the EXP- or the INF-growth, no significant correlation between the ISUP groups and ADC could be observed (p = 0.982 and p = 0.861, respectively).

Conclusion: PCa with INF-growth showed significantly lower SUV and higher ADC values compared to PCa with EXP-growth. Within the growth groups, ADC values were independent from ISUP grading.

Citing Articles

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.

Laudicella R, Bauckneht M, Burger I, Cacciola A, Fanti S, Farolfi A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39934300 DOI: 10.1007/s00259-025-07083-8.


FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.

Huang R, Zuo C, Mona C, Holzgreve A, Morrissey C, Nelson P J Nucl Med. 2024; 65(12):1952-1958.

PMID: 39477498 PMC: 11619584. DOI: 10.2967/jnumed.124.268037.


Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [Ga]Ga-PSMA-11 PET scans of primary prostate cancer.

Rupp N, Freiberger S, Ferraro D, Laudicella R, Heimer J, Muehlematter U Eur J Nucl Med Mol Imaging. 2024; 52(1):305-313.

PMID: 39083067 PMC: 11599624. DOI: 10.1007/s00259-024-06856-x.


Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [F]DCFPyL PET/CT imaging in PI-RADS 3/4 patients.

Fu Y, Zhao M, Chen J, Wen Q, Chen B Sci Rep. 2024; 14(1):15525.

PMID: 38969741 PMC: 11226634. DOI: 10.1038/s41598-024-65452-z.


Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals.

Miceli A, Liberini V, Pepe G, Dondi F, Vento A, Jonghi Lavarini L Diagnostics (Basel). 2024; 14(10).

PMID: 38786300 PMC: 11119694. DOI: 10.3390/diagnostics14101002.


References
1.
van der Leest M, Cornel E, Israel B, Hendriks R, Padhani A, Hoogenboom M . Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large.... Eur Urol. 2018; 75(4):570-578. DOI: 10.1016/j.eururo.2018.11.023. View

2.
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View

3.
Muller B, Shih J, Sankineni S, Marko J, Rais-Bahrami S, George A . Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology. 2015; 277(3):741-50. PMC: 4666087. DOI: 10.1148/radiol.2015142818. View

4.
Mortezavi A, Marzendorfer O, Donati O, Rizzi G, Rupp N, Wettstein M . Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. J Urol. 2018; 200(2):309-318. DOI: 10.1016/j.juro.2018.02.067. View

5.
Sahin M, Kizilay F, Guler E, Sarsik B, Harman M, Kalemci S . Multıparametric Prostate Magnetic Resonance Imaging Before Radical Prostatectomy: Can it Predict Histopathology?. Urol J. 2020; 18(4):417-421. DOI: 10.22037/uj.v16i7.6025. View